Xynos Konstantinos 4

What Happened

• Konstantinos Xynos, Chief Medical Officer of Replimune Group, was granted two awards on April 1, 2026: 50,000 restricted stock units (RSUs) and 75,000 derivative awards (stock option-style), each acquired at a $0.00 price. The combined awards represent 125,000 potential shares of Replimune common stock. These were grants/awards (compensation), not open-market purchases or sales.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 7, 2026 (filing marked late due to an inadvertent administrative error).
• Price: $0.00 for both awards (no cash paid by the insider).
• Amounts: 50,000 RSUs (Footnote F1) and 75,000 derivative shares/options (Footnote F2) — total 125,000 shares potentially issuable.
• Vesting (per filing footnotes):
  • F1 (RSUs): 25% vest on May 15, 2027; remaining vest in three roughly equal annual installments through May 15, 2030, subject to continuous service.
  • F2 (option-style): 25% of shares underlying the option vest on April 1, 2027; remaining shares vest in ~36 equal monthly installments thereafter.
• Shares owned after the transaction: not specified in the provided filing details.
• Timeliness: Filing late (reported reason: inadvertent administrative error). Late filings reduce immediate transparency but do not change the nature of the grants.

Context

• These awards are compensation tied to future vesting and continued service; they do not represent an immediate cash purchase or sale and therefore are not a direct market-confidence signal. RSUs convert to actual shares only as they vest; the option-style award similarly vests over time before shares are issuable or exercisable.